Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
European Urology|April 26, 2022
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP ConsortiumAmar U Kishan, Xiaoyan Wang, Yilun Sun, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Nature Genetics|February 12, 2008
Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles, Zsofia Kote-Jarai, Graham G Giles, et al.
Asian Journal of Andrology|December 4, 2008
Identification of new genetic risk factors for prostate cancerMichelle Guy, Zsofia Kote-Jarai, Graham G Giles, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
European Urology|April 26, 2022
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP ConsortiumAmar U Kishan, Xiaoyan Wang, Yilun Sun, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Nature Genetics|February 12, 2008
Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles, Zsofia Kote-Jarai, Graham G Giles, et al.
Asian Journal of Andrology|December 4, 2008
Identification of new genetic risk factors for prostate cancerMichelle Guy, Zsofia Kote-Jarai, Graham G Giles, et al.
Pageof 15